Trial Profile
HEALEY ALS Platform Trial
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 24 Apr 2024
Price :
$35
*
At a glance
- Drugs ABBV-CLS-7262 (Primary) ; CNM Au8 (Primary) ; DNL 343 (Primary) ; Pridopidine (Primary) ; Trehalose (Primary) ; Verdiperstat (Primary) ; Zilucoplan (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms HEALEY ALS
- 19 Mar 2024 Results published in the Media Release
- 19 Jan 2024 Results presented in a Prilenia Therapeutics Media Release.
- 08 Jan 2024 According to a Denali Therapeutics Inc media release, complete enrollment of participants in Regimen G (DNL343) in this trial expected in 2024.